VitalConnect, a San Jose, CA-based biosensor technology company, raised $100M in funding through a combination of equity and debt capital.
The equity financing was led by new investor Ally Bridge Group, with participation from existing investors, including EW Healthcare Partners, MVM and Revelation Partners while Trinity Capital provided the debt financing. In conjunction with the financing, VitalConnect expanded its Board of Directors with the addition of Steven Plachtyna from Ally Bridge Group and Eric Shiozaki from Revelation Partners.
The company intends to use the funds to accelerate its commercial expansion.
Led by CEO Peter Van Haur, VitalConnect is a leader in biosensor technology, rapidly expanding its presence in the ambulatory cardiac monitoring market. Vital Connect leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms that achieve better health and economic outcomes. Its products are designed for use in a broad range of remote and in-patient settings. The platform was designed to deliver better healthcare at lower costs while providing more convenience for the patients and healthcare providers.
FinSMEs
19/02/2025